Here, we present a case of a 56-year-old woman diagnosed with <i>KIF5B-MET</i> fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin. This evidence concerns the gene MET and non-small cell lung carcinoma.